IRVINE, Calif.--(BUSINESS WIRE)--TherOx, Inc., a privately held medical device company focused on improved treatment of Acute Myocardial Infarction (AMI), announced it has received U.S. Food and Drug ...
Prehospital pulse-dose glucocorticoid treatment in patients with ST-segment elevation myocardial infarction (STEMI) does not reduce the final infarct size at 3 months but may improve acute outcomes ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果